Oncology

Top news of the week in oncology and cancer drug development.

Top articles of the week from Specialty Pharmacy Times.

Ninety-three percent of women reported at least 1 adverse event from breast cancer treatment.

Researchers have found that depleting the environment of arginine plus a glutamine inhibitor may treat multiple types of cancer.

Immunotherapy also found to prolong life in patients with bladder cancer.

Young and middle-aged adults with colon cancer are 2 to 8 times more likely to receive postoperative chemotherapy.

Younger patients with colon cancer are more likely to be administered postoperative chemotherapy.

Cancer may be stopped by depriving cells of vital nutrients.

Combination treatment prior to surgery changes the clinical significance of growth factors as potential biomarkers.

Top news of the day from across the health care landscape.

Ductal carcinoma in situ influences risk of all-cause mortality.

A combination of 3 treatments successfully treated a canine with aggressive oral melanoma.

Patient with ductal carcinoma in situ had a lower risk of all-cause mortality compared with the general population.

Availability of new therapies and cost concerns create barriers for cancer patients.

Three studies presented at the European Cancer Congress highlight the need for cancer drug cost reform.

Findings may lead to increased survival in patients with glioblastoma.

PHLDB3 inhibits the p53 protein to promote tumor growth.

Study estimates 27% of men avoided an unnecessary biopsy for prostate cancer when given an MRI scan first.

Top news of the day from across the health care landscape.

PGAM1 inhibitors sensitize tumors to lynparza (Olaparib) treatment.

Statins degrade mutated p53 proteins, offering future cancer treatment.

Poor long-term survival rates for pediatric patients with acute megakaryoblastic leukemia.

PAN-301-1 is a vaccine candidate to treat patients with persistent prostate cancer.

Top news of the week in oncology and cancer drug development.

Increased use of biosimilars could create sustainable care for multiple chronic diseases.

Utilization of biosimilars has the potential to overhaul cancer treatment.

Cancer cells learn to cope with large scale DNA changes.

Simeprevir was approved by the FDA in late 2013 for hepatitis C virus.